Researchers from the Agharkar Research Institute (ARI), an autonomous institute under the Department of Science and Technology (DST), Government of India, have reported a biodegradable nanocarrier platform that delivers targeted gene therapy directly to breast cancer cells.

The study, recently published in the journal Advanced Healthcare Materials, highlights the potential of next-generation RNA-based therapeutics that can attack tumors with greater precision while minimizing damage to healthy tissues.

At the heart of the innovation is a specially engineered biodegradable mesoporous silica nanoparticle system designed to transport small interfering RNA (siRNA) molecules into tumor cells. 

These siRNAs work by silencing specific genes that enable cancer cells to survive, proliferate, and resist treatment.

One of the study's most notable achievements is its dual gene-silencing strategy. The nanocarrier simultaneously delivers siRNAs against MCL-1 and Survivin, two anti-apoptotic genes that play critical roles in helping tumors evade cell death and develop resistance to therapy.

Once the nanoparticles enter the tumor microenvironment, a glutathione-responsive mechanism triggers the controlled release of the therapeutic payload. This ensures that the gene-silencing molecules are released precisely where they are needed, maximizing therapeutic effectiveness.

The study was carried out by Niladri Haldar, Rajkumar Samanta, Surajit Patra, Devyani Sengar, Sachin Jadhav, and Virendra Gajbhiye from the Nanobioscience Group at ARI.

The findings were further validated in animal studies involving Severe Combined Immunodeficiency (SCID) mice. 

Laboratory studies using MCF-7 breast cancer models demonstrated significant suppression of both target genes, leading to enhanced apoptosis—or programmed cell death—and substantial inhibition of tumor growth.